Ignyta Investor Information

Ignyta, Inc. is writing a new story for cancer treatment, a story that features our distinctive Rx/Dx strategy to blaze a new path forward for patients.

Physicians discussing a patient chart

Our integrated approach combines precision therapeutics with companion molecular diagnostics for the potential benefit of patients with cancer.

Our people work daily to develop meaningful new drugs that target the molecular abnormalities of cancer, allowing us to advance precision therapies to treat each patient’s specific cancer.

We endeavor to eradicate residual disease in precisely defined patient populations by 2030, an audacious goal – backed by the unique combination of delivering the next generation of targeted therapeutics, accompanied by highly informative biomarkers for patient selection, treatment, and monitoring – that makes us confident we can help write the next chapter in the ever-changing story of cancer care.

To stay up to date on all Ignyta investor information, including Press Releases, Stock Information, SEC filings, and more, sign up for Ignyta email alerts.

Ignyta, Inc. (Nasdaq: RXDX) stock information, including a current stock ticker and historical trending.

View Stock Info

A sortable database of downloadable Ignyta, Inc. Press Releases from 2012 to present in PDF format.

Read Press Releases

A sortable database of Ignyta, Inc. SEC filings for all years 2013 to present, in HTML, PDF, and XLS formats.

View SEC Filings

Ignyta Events & Presentations

As a leader in biotechnology and precision medicine, the Ignyta team frequently presents at industry conferences and events, including clinical data, information on Ignyta clinical trials, and breakthroughs in the evolution of cancer treatment.

View Upcoming Events
Speaker in front of large group of people

Stock Information

Table scrolls to the right >>

15.80
current stock price
1 PM ET | Oct 20, 2017
Previous Close 16.65 Day High 16.50
Open 16.20 Day Low 15.63
Volume 7,390,747 52-Week High 18.30
Exchange NASDAQ 52-Week Low 4.15

Press Releases

Oct 19, 2017 Ignyta Announces Pricing of Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta"), a biotechnology company focused on precision medicine in oncology, today announced the pricing of an underwritten public offering of 10.0 million shares of its common stock at a price to the public of $1
Oct 18, 2017 Ignyta Announces Proposed Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta"), a biotechnology company focused on precision medicine in oncology, today announced that it has commenced an underwritten public offering of $125,000,000 of shares of its common stock. In connection with
Oct 17, 2017 Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
Entrectinib demonstrated a 78 percent (25 out of 32; by Investigator) and 69 percent (22 out of 32; by BICR) confirmed objective response rate (ORR) based on an interim analysis of patients with ROS1 fusion-positive advanced non-small cell lung cancer